Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

The molecule, called pyrene, is made up of four fused planar rings of carbon. It's therefore categorized as a polycyclic aromatic hydrocarbon (PAH) — one of the most abundant complex molecules ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

Keytruda is now under threat not only from ... the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Akeso shared data from its study, which indicated that ivonescimab ...

While 2028 Keytruda Patent Loss Weighs on Long-Term ... and relative size of its small molecule and biologics portfolios (as biologics are immune from Medicare negotiation for 13 years instead ...

The number of each atom collected is shown in the "Atoms Collected" area of the side panel. To create a molecule, make sure you have the right number of each atom and then select the correct “Create ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...